Sotera Health (NASDAQ:SHC) Shares Down 5.2% – Time to Sell?

Sotera Health (NASDAQ:SHC)’s stock price was down 5.2% on Wednesday . The company traded as low as $12.79 and last traded at $12.90. Approximately 851,002 shares traded hands during mid-day trading, a decline of 34% from the average daily volume of 1,298,385 shares. The stock had previously closed at $13.61.

Wall Street Analysts Forecast Growth

SHC has been the topic of a number of research reports. Barclays boosted their price objective on shares of Sotera Health from $14.00 to $17.00 and gave the stock an “overweight” rating in a research report on Tuesday, August 6th. Citigroup boosted their price objective on Sotera Health from $18.00 to $20.00 and gave the stock a “buy” rating in a research report on Wednesday, November 6th. Finally, Royal Bank of Canada restated an “outperform” rating and set a $17.00 price target on shares of Sotera Health in a research note on Tuesday, August 6th. Two investment analysts have rated the stock with a hold rating and four have assigned a buy rating to the company. According to data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average target price of $16.50.

Sotera Health Stock Down 3.6 %

The company has a quick ratio of 2.61, a current ratio of 2.88 and a debt-to-equity ratio of 4.91. The business’s 50-day moving average is $15.83 and its 200-day moving average is $13.95. The company has a market capitalization of $3.72 billion, a price-to-earnings ratio of 54.44 and a beta of 2.08.

Sotera Health (NASDAQ:SHC) last released its quarterly earnings results on Tuesday, November 5th. The company reported $0.17 earnings per share for the quarter, missing analysts’ consensus estimates of $0.18 by ($0.01). The business had revenue of $285.47 million for the quarter, compared to analysts’ expectations of $278.64 million. Sotera Health had a return on equity of 42.27% and a net margin of 6.31%. The business’s revenue for the quarter was up 8.5% compared to the same quarter last year. During the same quarter in the prior year, the company posted $0.18 earnings per share. As a group, equities analysts predict that Sotera Health will post 0.61 earnings per share for the current year.

Insider Transactions at Sotera Health

In other Sotera Health news, Director Gtcr Investment Xi Llc sold 10,000,000 shares of the stock in a transaction on Friday, September 6th. The shares were sold at an average price of $15.03, for a total value of $150,300,000.00. Following the completion of the sale, the director now directly owns 49,215,301 shares of the company’s stock, valued at $739,705,974.03. This represents a 16.89 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Corporate insiders own 55.12% of the company’s stock.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently made changes to their positions in SHC. True Wealth Design LLC acquired a new position in shares of Sotera Health during the third quarter worth $32,000. CWM LLC raised its stake in shares of Sotera Health by 86.1% in the second quarter. CWM LLC now owns 2,146 shares of the company’s stock valued at $25,000 after buying an additional 993 shares during the period. GAMMA Investing LLC grew its stake in Sotera Health by 125.0% in the 3rd quarter. GAMMA Investing LLC now owns 2,988 shares of the company’s stock valued at $50,000 after buying an additional 1,660 shares in the last quarter. Capital Performance Advisors LLP purchased a new position in Sotera Health during the third quarter worth about $91,000. Finally, Point72 DIFC Ltd raised its stake in Sotera Health by 556.6% in the second quarter. Point72 DIFC Ltd now owns 6,540 shares of the company’s stock valued at $78,000 after purchasing an additional 5,544 shares in the last quarter. Institutional investors and hedge funds own 91.03% of the company’s stock.

Sotera Health Company Profile

Sotera Health Company engages in the provision of sterilization, lab testing, and advisory services in the United States and internationally. The company operates through three segments: Sterigenics, Nordion, and Nelson Labs. It provides mission-critical end-to-end sterilization services, including gamma and electron beam irradiation, and ethylene oxide processing, as well as designs, installs, and maintains gamma irradiation systems.